Tudorza Pressair
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD)-associated bronchospasm, bronchitis, and emphysema. Tudorza Pressair received US and EU approvals for use in COPD in July 2012, and Japanese approval in March 2015. In Europe, the drug is marketed under the brand name Eklira Genuair.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Tudorza Pressair : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
10 Figure 1: Tudorza Pressair for COPD – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tudorza Pressair for COPD
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tudorza Pressair for COPD
14 Figure 4: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Tudorza Pressair drug profile
7 Table 2: Tudorza Pressair Phase III data in COPD
15 Table 3: Tudorza Pressair sales for COPD across the US, Japan, and major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Bevespi Aerosphere 
Sign up to the